Publications by authors named "Aurelia Prom"
Adjunctive ivermectin mass drug administration for malaria control on the Bijagos Archipelago of Guinea-Bissau (MATAMAL): a quadruple-blinded, cluster-randomised, placebo-controlled trial.
Lancet Infect Dis
November 2024
Background: Arthropod vectors feeding on the blood of individuals treated with ivermectin have substantially increased mortality. Whether this effect will translate into a useful tool for reducing malaria burden at scale is not clear. Our trial aimed to assess whether using ivermectin as an adjunct to mass drug administration (MDA) with dihydroartemisinin-piperaquine would further reduce malaria prevalence.
View Article and Find Full Text PDFBackground: Treatment of clinical Plasmodium falciparum malaria with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) is associated with increased post-treatment gametocyte carriage. The effect of seasonal malaria chemoprevention (SMC) with SP and AQ on gametocyte carriage was assessed in asymptomatic P. falciparum infected children.
View Article and Find Full Text PDFArticle Synopsis
- Mass drug administration (MDA) with dihydroartemisinin-piperaquine (DP) was tested in a study to evaluate its effect on reducing malaria transmission in low-transmission areas.
- The study found that there was a significant drop in malaria infection rates and clinical cases in 2014 and 2015 compared to 2013, with a coverage rate of over 65% for the drug.
- However, individuals previously infected had a higher risk of reinfection post-MDA, and while the intervention was effective in many areas, it was less successful in eastern Gambia, suggesting that targeted and repeated MDA could enhance malaria control.